Isis Pharmaceuticals Inc. and Eli Lilly and Co. have expanded their collaboration to develop cancer drugs based on a technology known as antisense.
Isis, a small biotechnology company based in Carlsbad, California, and drug giant Lilly, based in Indianapolis, said they had formed a two-year collaboration to discover drugs associated with specific genes that the companies believe are associated with cancer.
Last August, Lilly agreed to invest more than $200 million in an alliance with Isis.
The agreement included Lilly taking a 9 percent stake in Isis and rights to Isis’s experimental lung-cancer drug.
The companies agreed to jointly develop drugs in the fields of inflammatory and metabolic diseases.
The expanded alliance will focus on a number of antisense compounds currently in the preclinical stage of development.